Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US6911461 | UCB INC | 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
Feb, 2026
(2 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10729653 | UCB INC | Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives |
Apr, 2030
(6 years from now) |
Exclusivity | Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Aug 27, 2024 |
Market Authorisation Date: 12 May, 2016
Treatment: Treatment of partial-onset seizures in patients 4 years of age and older
Dosage: SOLUTION;INTRAVENOUS
14
United States
13
European Union
8
Iceland
7
China
6
Spain
6
Japan
6
Australia
5
Austria
5
Denmark
5
Germany
5
Russia
5
Norway
5
Korea, Republic of
4
Hong Kong
4
Malaysia
4
Poland
4
Israel
4
Bulgaria
4
Hungary
3
Czech Republic
3
Brazil
3
Canada
3
Portugal
3
Mexico
2
Yugoslavia
2
ME
2
Romania
2
Cyprus
2
Taiwan
2
Cuba
2
South Africa
2
Saudi Arabia
2
Colombia
2
Slovenia
1
RS
1
United Kingdom
1
EA
1
New Zealand
1
San Marino
1
Croatia
1
Belgium
1
Netherlands
1
Egypt
1
Lithuania
1
Luxembourg
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic